quinazolines has been researched along with ispinesib in 37 studies
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 0 (0.00) | 18.7374 |
| 1990's | 0 (0.00) | 18.2507 |
| 2000's | 16 (43.24) | 29.6817 |
| 2010's | 13 (35.14) | 24.3611 |
| 2020's | 8 (21.62) | 2.80 |
| Authors | Studies |
|---|---|
| D'Orazio, A; Reddy, K | 1 |
| Davis, DA; Hussain, M; Li, Y; Sarkar, FH; Sarkar, SH | 1 |
| Dar, M; Hodge, JP; Kathman, SJ; Williams, DH | 2 |
| Bright, J | 1 |
| Bélanger, K; Eisenhauer, EA; Lee, CW; Petrella, TM; Rao, SC; Savage, KJ; Seymour, L; Synold, TW; Tozer, RG; Wainman, N; Wood, L | 1 |
| Chen, EX; Chia, S; Colevas, AD; Hotte, SJ; Johnson, C; Pond, GR; Schwarz, JK; Siu, LL; Synold, TW; Tang, PA; Vasist, LS; Winquist, E | 1 |
| Biagi, JJ; Cripps, C; Eisenhauer, E; Feld, R; Gill, S; Knox, JJ; Major, P; Seymour, L; Synold, TW; Wainman, N | 1 |
| Carson, JD; Copeland, RA; Hartman, JJ; Lad, L; Luo, L; Sakowicz, R; Wood, KW | 1 |
| Blagden, SP; Bowen, C; Dar, MM; de Bono, JS; Hodge, JP; Kathman, SJ; Middleton, MR; Molife, LR; Payne, M; Protheroe, AS; Reid, AH; Seebaran, A; Vasist, LS; Williams, DD | 1 |
| Beekman, KE; Clark, JI; Davis, NB; Hussain, M; Lee, RT; Nichols, KF; Stadler, WM; Thomas, SP | 1 |
| Xu, W; Zhang, Y | 1 |
| Beer, TM; Crawford, ED; Dakhil, SR; Drelichman, A; Goldman, B; Hussain, MH; Lara, PN; Ryan, CW; Synold, TW; Van Veldhuizen, PJ; Vasist, LS | 1 |
| Bakker, A; Ferruzzi, P; Ghiron, C; Kremer, A; Lamanna, C; Nievo, M; Rossi, M; Valensin, S | 1 |
| Billups, CA; Carol, H; Gorlick, R; Houghton, PJ; Keir, ST; Kolb, EA; Lock, R; Maris, JM; Morton, CL; Reynolds, CP; Smith, MA | 1 |
| Basso, A; Duca, JS; Gray, K; Le, HV; Lesburg, CA; Mannarino, AF; Nale, L; Ogas, P; Prongay, AJ; Sheth, PR | 1 |
| Bean, P; Billig, J; Cases, S; Davis, J; Feiler, HS; Gray, JW; Kuo, WL; Martin, S; Purcell, JW; Reddy, M; Samayoa, K; Thomsen, K; Vo, H; Wood, KW; Ziyad, S | 1 |
| Boerner, SA; Burris, HA; Ho, PT; Hodge, JP; Jones, SF; Kathman, SJ; Lorusso, P; Pandite, L; Williams, DD | 1 |
| Adamson, PC; Blaney, SM; Conlan, MG; Dubowy, RL; Ingle, AM; Souid, AK; Sun, J | 1 |
| Annis, DA; Basso, AD; Chuang, CC; Gray, K; Herbst, R; Lahue, B; Le, HV; Ma, Y; Nickbarg, E; Sanden, D; Seghezzi, W; Sheth, PR; Shipps, GW; Smith, CK; Vilenchik, L | 1 |
| Chen, MM; Conlan, MG; Escandon, RD; Gomez, HL; Kiyan, M; Monsalvo, ML; Philco, M; Pimentel, P; Saikali, KG; Seroogy, JJ; Wolff, AA | 1 |
| Good, JA; Kaan, HY; Kozielski, F; Mackay, SP; Rath, O; Sutcliffe, OB; Wang, F | 1 |
| Kozielski, F; Schüttelkopf, AW; Talapatra, SK | 1 |
| Good, JA; Kaan, HY; Kozielski, F; MacKay, SP; Podgórski, D; Rath, O; Talapatra, SK; Wang, F | 1 |
| Braakhuis, BJ; Brakenhoff, RH; Martens-de Kemp, SR; Nagel, R; Stigter-van Walsum, M; van Beusechem, VW; van der Meulen, IH | 1 |
| Kaan, HY; Kozielski, F; Major, J; Rosenfeld, SS; Tkocz, K | 1 |
| Marzo, I; Naval, J | 1 |
| Elemento, O; Kapoor, TM; Kasap, C | 1 |
| Beck, D; Brandl, MB; Kavallaris, M; Li, F; Pasquier, E; Wong, ST; Zhang, S; Zhao, H | 1 |
| Crish, JF; Elmquist, WF; Gampa, G; Hinojosa, AQ; Kenchappa, RS; Kim, M; Luu, A; Mohammad, AS; Parrish, KE; Rosenfeld, SS; Sarkaria, JN; West, R | 1 |
| Budniok, A; Błauż, A; Hanif, M; Hartinger, CG; Jamieson, SMF; Leśniewska, B; Makal, A; Movassaghi, S; Plażuk, D; Reynisson, J; Rychlik, B; Söhnel, T; Tchoń, DM; Tong, KKH; Zafar, A; Łomzik, M | 1 |
| Abdollahi, A; Cao, J; Debus, J; Eddine, MA; Herold-Mende, C; Jungwirth, G; Moustafa, M; Unterberg, A; Warta, R; Yu, T | 1 |
| Akahoshi, K; Ban, D; Ishikawa, Y; Kudo, A; Murase, Y; Ogawa, K; Ono, H; Tanabe, M; Tanaka, S; Ueda, H; Yoshioka, R | 1 |
| Chen, L; Cheng, J; Ding, Y; Dong, G; Liu, R; Ma, J; Sheng, C; Wu, S; Wu, Y | 1 |
| He, N; Jiao, ZY; Li, LS; Ma, ZJ; Sun, RF; Yu, ZY; Zhang, GY | 1 |
| Guan, J; Qiao, Q; Song, Z; Wei, G | 1 |
| Ayine-Tora, DM; Błauż, A; Głodek, M; Hartinger, C; Makal, A; Plażuk, D; Rychlik, B; Tchoń, D; Łomzik, M | 1 |
2 review(s) available for quinazolines and ispinesib
| Article | Year |
|---|---|
Progress on kinesin spindle protein inhibitors as anti-cancer agents.
Topics: Adenosine Triphosphate; Antineoplastic Agents; Benzamides; Humans; Kinesins; Models, Biological; Models, Molecular; Neoplasms; Pyrimidines; Quinazolines; Spindle Apparatus; Thiones | 2008 |
Antimitotic drugs in cancer chemotherapy: promises and pitfalls.
Topics: Antimitotic Agents; Antineoplastic Agents; Benzamides; Clinical Trials as Topic; Cyclin-Dependent Kinases; Humans; Microtubules; Mitosis; Neoplasm Proteins; Neoplasms; Protein Kinase Inhibitors; Protein Serine-Threonine Kinases; Pyrazoles; Pyrimidines; Pyrimidinones; Quinazolines | 2013 |
11 trial(s) available for quinazolines and ispinesib
| Article | Year |
|---|---|
A Bayesian population PK-PD model of ispinesib-induced myelosuppression.
Topics: Adult; Aged; Aged, 80 and over; Antineoplastic Agents; Bayes Theorem; Benzamides; Dose-Response Relationship, Drug; Female; Humans; Leukocyte Count; Male; Markov Chains; Middle Aged; Models, Biological; Monte Carlo Method; Neutropenia; Quinazolines | 2007 |
A phase II study of ispinesib (SB-715992) in patients with metastatic or recurrent malignant melanoma: a National Cancer Institute of Canada Clinical Trials Group trial.
Topics: Adult; Aged; Aged, 80 and over; Antineoplastic Agents; Benzamides; Disease Progression; Drug Delivery Systems; Eye Neoplasms; Female; Humans; Kinesins; Male; Melanoma; Middle Aged; Mucous Membrane; Neoplasm Metastasis; Neoplasm Recurrence, Local; Quinazolines; Skin Neoplasms; Treatment Outcome | 2008 |
Phase II study of ispinesib in recurrent or metastatic squamous cell carcinoma of the head and neck.
Topics: Adult; Aged; Antineoplastic Agents; Benzamides; Carcinoma, Squamous Cell; Disease Progression; Disease-Free Survival; Female; Gene Expression; Head and Neck Neoplasms; Humans; Infusions, Intravenous; Kinesins; Leukopenia; Male; Middle Aged; Neoplasm Metastasis; Neoplasm Recurrence, Local; Neutropenia; Quinazolines; Treatment Outcome | 2008 |
A phase II and pharmacokinetic study of SB-715992, in patients with metastatic hepatocellular carcinoma: a study of the National Cancer Institute of Canada Clinical Trials Group (NCIC CTG IND.168).
Topics: Adult; Aged; Antineoplastic Agents; Benzamides; Carcinoma, Hepatocellular; Disease Progression; Female; Gene Expression; Humans; Infusions, Intravenous; Kinesins; Liver Neoplasms; Male; Middle Aged; Neoplasm Metastasis; Quinazolines; Treatment Outcome | 2008 |
A phase I trial of ispinesib, a kinesin spindle protein inhibitor, with docetaxel in patients with advanced solid tumours.
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Benzamides; Docetaxel; Female; Humans; Kinesins; Male; Middle Aged; Neoplasms; Quinazolines; Taxoids | 2008 |
A Bayesian population PK-PD model for ispinesib/docetaxel combination-induced myelosuppression.
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Bayes Theorem; Benzamides; Bone Marrow; Docetaxel; Dose-Response Relationship, Drug; Humans; Middle Aged; Quinazolines; Taxoids | 2009 |
A University of Chicago consortium phase II trial of SB-715992 in advanced renal cell cancer.
Topics: Aged; Aged, 80 and over; Benzamides; Carcinoma, Papillary; Carcinoma, Renal Cell; Chicago; Dose-Response Relationship, Drug; Female; Humans; Kidney Neoplasms; Male; Middle Aged; Prognosis; Quinazolines; Safety; Universities | 2008 |
Southwest Oncology Group phase II study of ispinesib in androgen-independent prostate cancer previously treated with taxanes.
Topics: Aged; Aged, 80 and over; Benzamides; Disease-Free Survival; Drug Evaluation; Drug Resistance, Neoplasm; Humans; Kinesins; Male; Middle Aged; Prostate-Specific Antigen; Prostatic Neoplasms; Quinazolines; Taxoids | 2008 |
A phase I study of ispinesib, a kinesin spindle protein inhibitor, administered weekly for three consecutive weeks of a 28-day cycle in patients with solid tumors.
Topics: Adult; Antineoplastic Agents; Benzamides; Demography; Dose-Response Relationship, Drug; Drug Administration Schedule; Female; Humans; Kinesins; Male; Neoplasms; Quinazolines; Spindle Apparatus | 2011 |
A pediatric phase I trial and pharmacokinetic study of ispinesib: a Children's Oncology Group phase I consortium study.
Topics: Adolescent; Benzamides; Child; Child, Preschool; Drug Administration Schedule; Female; Humans; Hyperbilirubinemia; Infant; Infusions, Intravenous; Kinesins; Maximum Tolerated Dose; Neoplasms; Neutropenia; Quinazolines; Young Adult | 2010 |
Phase I dose-escalation and pharmacokinetic study of ispinesib, a kinesin spindle protein inhibitor, administered on days 1 and 15 of a 28-day schedule in patients with no prior treatment for advanced breast cancer.
Topics: Adult; Alanine Transaminase; Anemia; Antineoplastic Agents; Aspartate Aminotransferases; Benzamides; Breast Neoplasms; Diarrhea; Drug Administration Schedule; Female; Humans; Kinesins; Maximum Tolerated Dose; Middle Aged; Quinazolines; Receptor, ErbB-2; Receptors, Estrogen; Receptors, Progesterone; Treatment Outcome | 2012 |
24 other study(ies) available for quinazolines and ispinesib
| Article | Year |
|---|---|
Highlights from the International Conference on Molecular Targets and Cancer Therapeutics: Discovery, Biology, And Clinical Applications, Philadelphia, PA, November 2005; ECCO 13--The European Cancer Conference, Paris, France, October 30-November 3, 2005.
Topics: Antibodies, Monoclonal; Antibodies, Monoclonal, Humanized; Antineoplastic Agents; Benzamides; Bevacizumab; Clinical Trials as Topic; Erlotinib Hydrochloride; Female; Humans; Kinesins; Male; Neoplasms; Quinazolines; Vinblastine | 2005 |
Increased therapeutic potential of an experimental anti-mitotic inhibitor SB715992 by genistein in PC-3 human prostate cancer cell line.
Topics: Antimitotic Agents; Antineoplastic Agents; Apoptosis; Benzamides; Blotting, Western; Cell Cycle; Cell Line, Tumor; Cell Proliferation; Cyclin-Dependent Kinase Inhibitor p21; DNA; DNA Primers; Drug Synergism; Enzyme-Linked Immunosorbent Assay; Gene Expression Regulation, Neoplastic; Genistein; Histones; Humans; Isoflavones; Kinesins; Male; Models, Statistical; Oligonucleotide Array Sequence Analysis; Prostatic Neoplasms; Proto-Oncogene Proteins c-akt; Quinazolines; Reverse Transcriptase Polymerase Chain Reaction; RNA; Signal Transduction; Spindle Apparatus; Tetrazolium Salts; Thiazoles | 2006 |
American Chemical Society--233rd National Meeting. Kinesin spindle protein inhibitors. 25-29 March 2007, Chicago, IL, USA.
Topics: Animals; Antineoplastic Agents; Benzamides; Drug Delivery Systems; Drug Design; Drug Screening Assays, Antitumor; Drugs, Investigational; Humans; Kinesins; Neoplasms; Pyrimidinones; Quinazolines; Spindle Apparatus | 2007 |
Mechanism of inhibition of human KSP by ispinesib.
Topics: Adenosine Diphosphate; Adenosine Triphosphatases; Adenosine Triphosphate; Allosteric Regulation; Benzamides; Binding, Competitive; Enzyme Inhibitors; Humans; Kinesins; Microtubules; Models, Biological; Models, Chemical; Protein Binding; Protein Structure, Tertiary; Quinazolines | 2008 |
KIF11 inhibition for glioblastoma treatment: reason to hope or a struggle with the brain?
Topics: Animals; Antineoplastic Agents; Astrocytes; Benzamides; Brain Neoplasms; Cell Cycle; Cell Line, Tumor; Cerebral Cortex; Gene Expression Profiling; Gene Expression Regulation, Neoplastic; Glioblastoma; Humans; Kinesins; Quinazolines; Rats; Spindle Apparatus | 2009 |
Initial testing (stage 1) of the kinesin spindle protein inhibitor ispinesib by the pediatric preclinical testing program.
Topics: Animals; Antimitotic Agents; Antineoplastic Agents; Benzamides; Cell Line, Tumor; Female; Glioblastoma; Humans; Injections, Intraperitoneal; Kinesins; Leukemia, Experimental; Mice; Mice, Inbred BALB C; Mice, SCID; Osteosarcoma; Quinazolines; Rhabdoid Tumor; Rhabdomyosarcoma; Sarcoma, Ewing; Single-Blind Method; Spindle Apparatus; Tumor Stem Cell Assay; Wilms Tumor; Xenograft Model Antitumor Assays | 2009 |
Thermodynamics of nucleotide and inhibitor binding to wild-type and ispinesib-resistant forms of human kinesin spindle protein.
Topics: Adenosine Diphosphate; Adenosine Triphosphatases; Adenosine Triphosphate; Amino Acid Substitution; Benzamides; Biocatalysis; Calorimetry; Circular Dichroism; Drug Resistance, Neoplasm; Enzyme Inhibitors; Humans; Kinesins; Kinetics; Magnesium; Models, Molecular; Nucleotides; Protein Binding; Protein Structure, Tertiary; Pyrimidines; Quinazolines; Recombinant Fusion Proteins; Temperature; Thermodynamics; Thiones; Transition Temperature | 2009 |
Activity of the kinesin spindle protein inhibitor ispinesib (SB-715992) in models of breast cancer.
Topics: Animals; Antineoplastic Agents; Apoptosis; Benzamides; Breast Neoplasms; Carcinoma; Cell Line, Tumor; Dose-Response Relationship, Drug; Drug Resistance, Neoplasm; Female; Humans; Kinesins; Mice; Mice, Nude; Mice, SCID; Quinazolines; Xenograft Model Antitumor Assays | 2010 |
Novel benzimidazole inhibitors bind to a unique site in the kinesin spindle protein motor domain.
Topics: Adenosine Triphosphatases; Antineoplastic Agents; Benzamides; Benzimidazoles; Binding Sites; Circular Dichroism; Humans; Kinesins; Mass Spectrometry; Nucleotides; Protein Structure, Tertiary; Quinazolines | 2010 |
Triphenylbutanamines: kinesin spindle protein inhibitors with in vivo antitumor activity.
Topics: Animals; Antineoplastic Agents; Benzamides; Benzene Derivatives; Biological Availability; Butylamines; Cell Line, Tumor; Drug Screening Assays, Antitumor; Female; Humans; Kinesins; Mice; Mice, Nude; Models, Molecular; Molecular Structure; Neoplasm Transplantation; Protein Binding; Protein Conformation; Quinazolines; Stereoisomerism; Structure-Activity Relationship; Transplantation, Heterologous | 2012 |
The structure of the ternary Eg5-ADP-ispinesib complex.
Topics: Adenosine Diphosphate; Benzamides; Crystallography, X-Ray; Humans; Kinesins; Magnesium; Molecular Motor Proteins; Multiprotein Complexes; Protein Binding; Quinazolines | 2012 |
Optimized S-trityl-L-cysteine-based inhibitors of kinesin spindle protein with potent in vivo antitumor activity in lung cancer xenograft models.
Topics: Animals; Antineoplastic Agents; Benzamides; Butylamines; Cell Line, Tumor; Chromones; Cysteine; Kinesins; Lung Neoplasms; Mice; Mice, Nude; Neoplasm Transplantation; Quinazolines; Structure-Activity Relationship; Transplantation, Heterologous | 2013 |
Functional genetic screens identify genes essential for tumor cell survival in head and neck and lung cancer.
Topics: Animals; Benzamides; beta Karyopherins; Blotting, Western; Carcinoma, Non-Small-Cell Lung; Carcinoma, Squamous Cell; Cell Cycle Proteins; Cell Line, Tumor; Cell Survival; Cells, Cultured; Dose-Response Relationship, Drug; G2 Phase Cell Cycle Checkpoints; Genes, Essential; Genome-Wide Association Study; Head and Neck Neoplasms; Humans; Kinesins; Lung Neoplasms; Mice; Microtubule-Associated Proteins; Nuclear Proteins; Quinazolines; ran GTP-Binding Protein; Reverse Transcriptase Polymerase Chain Reaction; RNA Interference; Tumor Burden; Xenograft Model Antitumor Assays | 2013 |
"Snapshots" of ispinesib-induced conformational changes in the mitotic kinesin Eg5.
Topics: Algorithms; Benzamides; Binding Sites; Biocatalysis; Crystallography, X-Ray; Humans; Kinesins; Kinetics; Mitosis; Models, Molecular; Molecular Structure; Protein Binding; Protein Conformation; Protein Structure, Secondary; Protein Structure, Tertiary; Quinazolines | 2013 |
DrugTargetSeqR: a genomics- and CRISPR-Cas9-based method to analyze drug targets.
Topics: Antineoplastic Agents; Benzamides; Cell Line, Tumor; Clustered Regularly Interspaced Short Palindromic Repeats; Drug Resistance, Neoplasm; Endonucleases; Epigenesis, Genetic; Genome; High-Throughput Nucleotide Sequencing; Humans; Imidazoles; Kinesins; Molecular Targeted Therapy; Mutation; Naphthoquinones; Quinazolines | 2014 |
Computational analysis of image-based drug profiling predicts synergistic drug combinations: applications in triple-negative breast cancer.
Topics: Animals; Apoptosis; Benzamides; Cell Line, Tumor; Drug Synergism; Female; Humans; Kinesins; Mice; Mice, Inbred BALB C; Mitosis; Pyrimidines; Quinazolines; Thiones; Triple Negative Breast Neoplasms; Vinblastine; Xenograft Model Antitumor Assays | 2014 |
Enhancing Brain Retention of a KIF11 Inhibitor Significantly Improves its Efficacy in a Mouse Model of Glioblastoma.
Topics: Acridines; Animals; ATP Binding Cassette Transporter, Subfamily B; ATP Binding Cassette Transporter, Subfamily G, Member 2; Benzamides; Blood-Brain Barrier; Brain; Cell Line, Tumor; Cell Proliferation; Disease Models, Animal; Glioblastoma; Humans; Kinesins; Mice; Molecular Targeted Therapy; Neoplasm Invasiveness; Neoplasm Proteins; Quinazolines; Tetrahydroisoquinolines; Xenograft Model Antitumor Assays | 2020 |
Metal-Dependent Cytotoxic and Kinesin Spindle Protein Inhibitory Activity of Ru, Os, Rh, and Ir Half-Sandwich Complexes of Ispinesib-Derived Ligands.
Topics: Antineoplastic Agents; Antioxidants; Benzamides; Cell Line, Tumor; Cell Proliferation; Coordination Complexes; Drug Screening Assays, Antitumor; Humans; Kinesins; Ligands; Metals, Heavy; Molecular Docking Simulation; Protein Binding; Quinazolines; Stereoisomerism | 2020 |
KIF11 inhibitors filanesib and ispinesib inhibit meningioma growth in vitro and in vivo.
Topics: Animals; Benzamides; Cell Line, Tumor; Cell Proliferation; Female; G2 Phase Cell Cycle Checkpoints; Humans; Kinesins; Meningeal Neoplasms; Meningioma; Mice; Quinazolines; Thiadiazoles; Xenograft Model Antitumor Assays | 2021 |
Inhibitor library screening identifies ispinesib as a new potential chemotherapeutic agent for pancreatic cancers.
Topics: Analysis of Variance; Animals; Antineoplastic Agents; Apoptosis; Benzamides; Cell Line, Tumor; Cell Proliferation; Disease-Free Survival; Drug Discovery; Female; Gene Silencing; Humans; Kinesins; Libraries, Special; Metaphase; Mice; Mice, Nude; Neoplasm Proteins; Pancreatic Neoplasms; Quinazolines; Tumor Burden; Xenograft Model Antitumor Assays | 2021 |
Ispinesib as an Effective Warhead for the Design of Autophagosome-Tethering Chimeras: Discovery of Potent Degraders of Nicotinamide Phosphoribosyltransferase (NAMPT).
Topics: Autophagosomes; Benzamides; Chimera; Cytokines; Enzyme Inhibitors; Nicotinamide Phosphoribosyltransferase; Quinazolines | 2022 |
Combined Inhibition of KIF11 and KIF15 as an Effective Therapeutic Strategy for Gastric Cancer.
Topics: Benzamides; Cell Line, Tumor; Humans; Kinesins; Quinazolines; Stomach Neoplasms | 2023 |
Distinct binding interactions trigger opposite conformational modulations on pathogenic and wildtype Huntingtin exon 1 proteins.
Topics: Exons; Huntingtin Protein; Intrinsically Disordered Proteins; Quinazolines | 2022 |
Organometallic Ru, Os, Rh and Ir half-sandwich conjugates of ispinesib - impact of the organometallic group on the antimitotic activity.
Topics: Antimitotic Agents; Antineoplastic Agents; Benzamides; Organometallic Compounds; Quinazolines; Reactive Oxygen Species | 2023 |